CTIX future (KEVETRIN) in this man's hands!

Principal Investigator:
Geoffrey Shapiro, M.D., Ph.D.

Principal Investigator Bio:
Dr. Shapiro is an Assistant Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School, where he performs basic, translational and clinical research in the field of cell cycle therapeutics. His major research interest is the assessment of cyclin-dependent kinases, mitotic kinases and checkpoint kinases as anti-neoplastic drug targets, both alone and in concert with DNA damaging agents. He has also developed pharmacodynamic assays for these targets that are applicable to preclinical and clinical investigation. He is a member of the Dana-Farber/Harvard Cancer Center Specialized Programs of Research Excellence (SPORE) in lung cancer and breast cancer. Additionally, he serves as the Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, and oversees the conduct of Phase 1 and Proof of Mechanism Trials for patients with advanced solid tumors. Geoffrey I. Shapiro, M.D., Ph.D. Dana-Farber Cancer Institute